Vixen Bio

Bio is a bioanalytical innovation company dedicated to accelerating and de-risking immunotherapy development through unparalleled immunoassay precision. Operating at the intersection of immunology and advanced analytics, Vixen Bio empowers antibody and cell therapy programs by combining proprietary kinetic and hybrid immunoassays with real-time, live-cell functional bioassays in complex biological samples. This delivers early clinically relevant insights and predictive understanding of human immune responses for pharmaceutical, biotech, and clinical development partners -from discovery through clinical trials.

Their integrated analytical platforms provide early target and functional affinity insights that guide candidate selection during lead optimization. By combining kinetic profiling of biologicals with targets and Fc receptors, structural characterization through e.g. mass spectrometry, and functional immune cell assays into one streamlined workflow, Vixen Bio enables early-stage characterization across all relevant functional domains. This exhaustive approach significantly reduces failures, unnecessary optimization rounds, and development costs, maximizing return on R&D investment while accelerating innovation.

A strong example of this integrated methodology is Vixen Bio’s work in monoclonal antibody optimization. Through data-rich, all-in-one analytical workflows, the company evaluates yield, Fc functionality, Fab target affinity, and structural integrity directly from supernatant. By linking affinity shifts to post-translational modifications identified via peptide mapping and glycoform analysis, Vixen Bio provides robust, data-driven insights that allow reliable early candidate selection. This approach not only enhances scientific understanding but also supports efficient regulatory filing procedures and strategic decision-making. 

Beyond early discovery, Vixen Bio also contributes to more efficient and successful clinical development through biomarker-driven strategies and personalised patient immune-profiling. By enabling precise patient stratification and monitoring in physiologically relevant conditions, the company helps improve trial design, increase efficacy signals, and reduce costs. In an era where biologics and CAR-T therapies demand highly targeted patient populations, such precision approaches can significantly reduce trial sizes, accelerate timelines, and enhance the probability of regulatory approval.

As an associated partner of the OncoProTools Doctoral Network, Vixen Bio plays an active role in bridging academic research and industrial applications. Within this Marie Skłodowska-Curie Action, Vixen Bio has hosted two Doctoral Candidates for research secondments focused on the development of new assays for Granzyme B and Fibroblast Activation Protein (FAP). During this research stay, the fellows have received hands-on training in advanced bioanalytical assay development, gaining first-hand experience in translating immunological concepts into robust analytical tools suitable for therapeutic and diagnostic applications.

This collaboration offers an excellent opportunity for the Doctoral Candidates to gain first-hand experience in an industrial R&D environment. In this way, Vixen Bio makes a significant contribution to the interdisciplinary and intersectoral training objectives of the OncoProTools Doctoral Network, equipping the next generation of scientists with the skills needed to become leaders in tomorrow’s research and innovation (R&I) in patient-centred oncotherapy and diagnostics. 

Learn more about Vixen Bio: https://vixenbio.com/​

Or follow for regular updates: https://Linkedin.com/company/vixenBio